Bayer AG says US Patent Trial and Appeal Board wrongly cancelled Xarelto patent
MLex Summary: Bayer Pharma Aktiengesellschaft is seeking to undo findings by the US Patent Trial and Appeal Board that its US Patent No. 10,828,310 is rendered obvious and anticipated by prior art.See...To view the full article, register now.
Already a subscriber? Click here to view full article